Scientific deep-dive
Victoza (Liraglutide 1.8 mg): Evidence Review, Side Effects, Generic
Victoza is liraglutide 1.8 mg — the first daily GLP-1 receptor agonist, FDA-approved in 2010 for type 2 diabetes. Same molecule as Saxenda at lower dose. LEAD and LEADER trial data, FDA-label side effects, generic liraglutide since 2024, and how Victoza fits in 2026.
Victoza is liraglutide 1.8 mg — a once-daily GLP-1 receptor agonist injection from Novo Nordisk, FDA-approved January 25, 2010 for type 2 diabetes[12]. It was the first daily GLP-1 RA on the US market and remained the category leader until once-weekly Ozempic launched in 2017. Today, in 2026, Victoza is still on the market, has a hard cardiovascular indication from the LEADER trial[8], and now has two generic versions: Hikma generic liraglutide (approved December 2024, the first generic GLP-1 receptor agonist approved in the US)[13] and Teva generic liraglutide 3 mg for the Saxenda weight-management indication (approved August 2025)[14].
Honest answer — in one paragraph
Victoza is liraglutide 1.8 mg — the first daily GLP-1 receptor agonist, FDA-approved in 2010 for type 2 diabetes. It causes modest weight loss as a secondary effect, but Saxenda (the same drug at 3.0 mg) is the FDA-approved weight-management version. Hikma’s generic launched December 2024.
Magnitude comparison
Weight-loss magnitude across once-daily liraglutide doses (Victoza 1.8 mg in T2D, Saxenda 3.0 mg in obesity) compared with the leading once-weekly GLP-1 and dual-agonist therapies. Victoza weight loss is from LEAD-6 (1.8 mg, 26 weeks; other LEAD trials ranged from 0.2 kg alongside glimepiride to 2.0 kg with metformin plus a thiazolidinedione); Saxenda is from SCALE Obesity at 56 weeks; STEP-1 and SURMOUNT-1 are 68-72 week chronic-weight-management trials.[6][9]
- Victoza — liraglutide 1.8 mg daily (LEAD-6, T2D, 26 wk)3.2 kg weight lossBuse 2009 Lancet (LEAD-6) PMID 19515413
- Saxenda — liraglutide 3.0 mg daily (SCALE Obesity, 56 wk)8.0 % body weightPi-Sunyer 2015 NEJM PMID 26132939
- Wegovy — semaglutide 2.4 mg weekly (STEP-1, 68 wk)14.9 % body weightWilding 2021 NEJM PMID 33567185
- Zepbound — tirzepatide 15 mg weekly (SURMOUNT-1, 72 wk)20.9 % body weightJastreboff 2022 NEJM PMID 35658024
What is Victoza?
Victoza is the brand name for liraglutide injection 6 mg/mL, manufactured by Novo Nordisk. It comes in a prefilled multi-dose pen (18 mg / 3 mL) and is titrated from 0.6 mg to 1.2 mg to a maximum maintenance dose of 1.8 mg once daily as a subcutaneous injection[10]. Victoza was approved by the FDA on January 25, 2010 (NDA 022341) for improving glycemic control in adults with type 2 diabetes, making it the first daily GLP-1 receptor agonist approved in the United States[12]. Byetta (exenatide twice-daily) preceded it by four years (2005), but Victoza was the first once-daily GLP-1 RA and a human GLP-1 analog[6], engineered to be 97% homologous to native human GLP-1 per its label[10].
Mechanistically, liraglutide is a long-acting GLP-1 receptor agonist that lowers blood glucose by enhancing glucose-dependent insulin secretion, suppressing inappropriate glucagon release, and slowing gastric emptying. As a secondary effect — mediated by the central GLP-1 receptor in the hypothalamus and brainstem — it suppresses appetite and food intake, which produces modest weight loss in adults with type 2 diabetes (on 1.8 mg over 26 weeks, mean loss was 2.0 kg with metformin plus a thiazolidinedione and 3.24 kg in the comparison with exenatide, but only 0.2 kg when added to glimepiride)[4][6][1]. Liraglutide’s ~13-hour half-life supports once-daily dosing — meaningfully shorter than once-weekly semaglutide (~165 hours) but meaningfully longer than the 2.4-hour half-life of native GLP-1.
Important: Victoza is FDA-approved only for type 2 diabetes, not for chronic weight management. The FDA-approved weight-management version of liraglutide is Saxenda (NDA 206321, approved December 23, 2014), dosed at 3.0 mg once daily — the same active ingredient at a 1.67× higher dose for a different indication[11]. The weekly step-up to that dose is in our Saxenda dosing chart.
Victoza vs Saxenda (same drug, different dose)
Victoza and Saxenda are both liraglutide injection 6 mg/mL in a 3 mL multi-dose pen — the same molecule, the same vial concentration, the same manufacturer (Novo Nordisk), the same active ingredient on FDA filings. They differ in maximum dose, FDA indication, and labeling.
| Victoza | Saxenda | |
|---|---|---|
| Active ingredient | Liraglutide 6 mg/mL | Liraglutide 6 mg/mL |
| Max daily dose | 1.8 mg | 3.0 mg |
| FDA application | NDA 022341 | NDA 206321 |
| Original approval | Jan 25, 2010 | Dec 23, 2014 |
| FDA indication | Type 2 diabetes; CV-risk reduction in T2D with established CVD | Chronic weight management in adults with obesity, or overweight with a comorbidity (SCALE trials enrolled BMI ≥ 30, or ≥ 27 with comorbidity); pediatric obesity ages 12+ (body weight > 60 kg) |
| Pivotal trial program | LEAD-1 through LEAD-6 (T2D); LEADER (CV outcomes) | SCALE Obesity & Prediabetes; SCALE Maintenance; SCALE Diabetes |
| Mean weight loss | ~0.2–3.2 kg at 26 wk on 1.8 mg (LEAD) | ~8.0% body weight at 56 wk (SCALE) |
| Generic available | Hikma (Dec 2024) | Teva (Aug 2025) |
Because Victoza and Saxenda contain the same molecule at the same vial concentration, the multi-dose pens are pharmacologically fungible — the same 3 mL cartridge can deliver any dose from 0.6 mg up to 3.0 mg in 0.6 mg increments. The two products differ in FDA-approved labeled use and in the dose at which the pen’s titration stops. Prescribing Victoza off-label at 3.0 mg/day to chase the Saxenda effect size is dose-escalating outside the FDA-approved label and is not a substitute for the Saxenda indication.
Victoza side effects from the LEAD trials and FDA label
Victoza’s registrational program was the LEAD trial family (Liraglutide Effect and Action in Diabetes) — six Phase 3 trials in adults with type 2 diabetes, each pairing liraglutide with a different background therapy or comparator. The integrated safety profile from LEAD 1–5 was published by Blonde and Russell-Jones in 2009[7].
The six LEAD trials
| Trial | Comparator | Background therapy | Duration | Primary publication |
|---|---|---|---|---|
| LEAD-1 SU | Rosiglitazone, placebo | Sulphonylurea (glimepiride) | 26 weeks | Marre 2009 Diabet Med[1] |
| LEAD-2 Met | Glimepiride, placebo | Metformin | 26 weeks | Nauck 2009 Diabetes Care[2] |
| LEAD-3 Mono | Glimepiride | Monotherapy | 52 weeks | Garber 2009 Lancet[3] |
| LEAD-4 Met+TZD | Placebo | Metformin + rosiglitazone | 26 weeks | Zinman 2009 Diabetes Care[4] |
| LEAD-5 Met+SU | Insulin glargine, placebo | Metformin + glimepiride | 26 weeks | Russell-Jones 2009 Diabetologia[5] |
| LEAD-6 | Exenatide twice daily | Metformin and/or SU | 26 weeks | Buse 2009 Lancet[6] |
Side-effect pattern across LEAD 1-5
In the pooled LEAD 1-5 overview, the most frequently reported adverse events with liraglutide were gastrointestinal — nausea, vomiting, and diarrhea[7]. The nausea rate was highest in the first 4–6 weeks of titration and decreased substantially over time. Per the Victoza label, withdrawals due to gastrointestinal adverse reactions occurred in 4.3% of Victoza-treated patients versus 0.5% on placebo in a pool of 5 placebo-controlled glycemic trials, mainly during the first 2 to 3 months[10]. Hypoglycemia rates were low when liraglutide was used as monotherapy or with metformin, but rose meaningfully when combined with a sulphonylurea — consistent with the established class effect.
The FDA Victoza prescribing information[10] lists the following boxed warning and warnings:
- Boxed warning: thyroid C-cell tumors. Liraglutide causes thyroid C-cell tumors at clinically relevant exposures in rodents. The human relevance is unknown. Victoza is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Pancreatitis. Acute pancreatitis, including hemorrhagic and necrotizing pancreatitis, has been observed. Discontinue if pancreatitis is suspected.
- Hypoglycemia. Increased risk when combined with insulin secretagogues (e.g. sulphonylureas) or insulin.
- Acute kidney injury. Reported in patients with severe dehydration secondary to GI side effects.
- Hypersensitivity reactions. Including anaphylaxis and angioedema.
- Acute gallbladder disease. Cholelithiasis and cholecystitis have been observed in liraglutide trials and the broader GLP-1 class.
The full label is published as DailyMed SetID 5a9ef4ea-c76a-4d34-a604-27c5b505f5a4 (Novo Nordisk) [10]. The class warnings are shared with Saxenda, Ozempic, Wegovy, Mounjaro, and Zepbound. Our GLP-1 side effects evidence review walks through the full class-wide side-effect taxonomy with the verbatim FDA-label quotes for each drug.
Victoza for cardiovascular protection (LEADER trial)
The single largest piece of Victoza-specific evidence beyond the LEAD glycemic-control program is the LEADER trial (Marso 2016 N Engl J Med, PMID 27295427)[8] — a placebo-controlled cardiovascular outcomes trial of 9,340 adults with type 2 diabetes and established cardiovascular disease, or at high cardiovascular risk, randomized to liraglutide 1.8 mg/day (Victoza dosing) vs placebo on top of standard care. Median follow-up was 3.8 years.
The primary composite outcome was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke (3-point MACE). LEADER reported:
- Primary endpoint: 13.0% of liraglutide-treated participants had a 3-point MACE event vs 14.9% of placebo-treated participants — hazard ratio 0.87 (95% CI 0.78–0.97; p=0.01 for superiority).
- Cardiovascular mortality: hazard ratio 0.78 (95% CI 0.66–0.93).
- All-cause mortality: hazard ratio 0.85 (95% CI 0.74–0.97).
- Adverse events broadly consistent with the LEAD program; no excess pancreatitis or pancreatic cancer signal identified in the trial.
LEADER was the first GLP-1 cardiovascular outcomes trial to demonstrate superiority (not just non-inferiority) on the 3-point MACE primary endpoint in adults with type 2 diabetes. The FDA added a cardiovascular risk-reduction indication to the Victoza label on August 25, 2017 based on the LEADER result[12], making Victoza the first GLP-1 RA in the United States with a hard cardiovascular indication. Ozempic (SUSTAIN-6) followed in 2020.
LEADER is also the closest analog in the GLP-1 portfolio to the SELECT trial that later anchored Wegovy’s cardiovascular indication in adults without diabetes. See our SELECT trial review for the non-diabetic CV-outcomes story; the two trials together establish a class-level cardiovascular benefit for GLP-1 receptor agonists, with each agent independently anchored to its own randomized trial.
Generic liraglutide: Hikma 2024, Teva 2025
The Victoza-vs-Saxenda generic landscape changed substantially in late 2024 and 2025. Both reference products now have FDA-approved generics.
Hikma generic liraglutide (Victoza reference)
FDA application: ANDA 215503.
Approval date: December 23, 2024.
Sponsor: Hikma Pharmaceuticals USA Inc.
Strength: liraglutide 6 mg/mL, supplied as an 18 mg / 3 mL multi-dose prefilled pen — bioequivalent to Victoza (TE code AP1).
Indication: type 2 diabetes (matches the Victoza listed-drug label).
Significance: the first generic GLP-1 receptor agonist approved in the United States. The FDA press release at the time of approval described the approval as a milestone for generic GLP-1 access[13].
Teva generic liraglutide 3 mg (Saxenda reference)
FDA application: ANDA 214568.
Approval date: August 27, 2025.
Sponsor: Teva Pharmaceuticals USA.
Strength: liraglutide 6 mg/mL, supplied as an 18 mg / 3 mL multi-dose prefilled pen, dosed up to 3.0 mg per day for chronic weight management.
Indication: chronic weight management in adults with obesity or overweight plus a weight-related comorbidity, and pediatric obesity ages 12+ (matches the Saxenda listed-drug label).
Significance: the first generic GLP-1 receptor agonist for weight management approved in the United States[14].
The clinical implication: as of mid-2025, both Victoza (1.8 mg/day, T2D) and Saxenda (3.0 mg/day, weight management) have a generic-equivalent option. Liraglutide is now the only GLP-1 receptor agonist molecule with FDA-approved generics in any indication. Semaglutide (Ozempic / Wegovy / Rybelsus) and tirzepatide (Mounjaro / Zepbound) remain branded-only through their FDA-approved patent and exclusivity periods.
Victoza for weight loss (off-label) — what to expect
Victoza is not FDA-approved for chronic weight management, and the FDA-approved version of liraglutide for that purpose is Saxenda. Some prescribers nonetheless prescribe Victoza off-label for weight loss in patients without diabetes, because the active ingredient and the multi-dose pen are identical to Saxenda — only the maximum titrated dose differs. For the weight-loss version, our guide to getting Saxenda online covers the telehealth steps.
Realistic expectations for Victoza-dose (1.8 mg/day) off-label weight loss, anchored to the LEAD trial program (T2D population)[7]:
- Mean weight loss in T2D: about 0.2–3.2 kg at 26 weeks at the 1.8 mg/day dose, depending on the background therapy: 0.2 kg when added to glimepiride, 2.0 kg with metformin plus a thiazolidinedione and 3.24 kg in the comparison with exenatide[1][4][6]. A sulphonylurea background can blunt GLP-1 weight loss.
- Saxenda dose (3.0 mg/day) reference: ~8.0% mean body weight loss at 56 weeks in the SCALE Obesity trial[9] — meaningfully larger than the 1.8 mg dose. The dose-response is real.
- How it stacks against the modern injectables: ~5× less mean weight loss than tirzepatide 15 mg (SURMOUNT-1, ~20.9% at 72 weeks) and ~3× less than semaglutide 2.4 mg (STEP-1, ~14.9% at 68 weeks). See our weight-loss injections guide for the full magnitude comparison.
Clinical bottom line: if the goal is glycemic control in type 2 diabetes with a cardiovascular-benefit indication, Victoza (1.8 mg) is a clinically reasonable choice with a hard CV outcomes trial behind it[8]. If the goal is chronic weight management without diabetes, the FDA-approved choice in the liraglutide molecule is Saxenda (3.0 mg). And if the goal is the largest weight-loss magnitude available, the GLP-1 class has moved past liraglutide entirely — once-weekly semaglutide (Wegovy) and the dual-agonist tirzepatide (Zepbound) both deliver substantially more weight loss in head-to-head magnitude.
How Victoza fits in 2026 (vs Ozempic, Mounjaro, Wegovy, Zepbound)
Victoza is now 16 years post-approval and the GLP-1 class has expanded significantly around it. Where does Victoza still fit?
When Victoza is still prescribed in 2026
- Type 2 diabetes patient with established CVD. The LEADER trial benefit is liraglutide-specific (HR 0.87 on 3-point MACE)[8]. While semaglutide (SUSTAIN-6, SELECT) and dulaglutide (REWIND) have similar benefits, Victoza is one of the few GLP-1 RAs with a dedicated cardiovascular outcomes trial in a T2D-CVD population at a daily dose.
- Patients who need a daily dosing schedule rather than weekly. Some patients prefer the daily dosing rhythm for adherence; some have side-effect tolerability that’s better with daily exposure than weekly peak-trough cycling.
- Cost-sensitive patients in T2D where Hikma generic liraglutide is on formulary. The Hikma generic (approved December 2024)[13] creates a cost path that does not exist for Ozempic, Mounjaro, Wegovy, or Zepbound.
- Patients with intolerance or insurance denial of tirzepatide/semaglutide. When step therapy requires a GLP-1 trial before tirzepatide, Victoza or generic liraglutide is sometimes the cheapest gateway option.
When Victoza is not the best choice in 2026
- Primary goal is chronic weight management. Use Saxenda (or Teva generic liraglutide 3 mg) for the FDA-approved indication; or consider Wegovy / Zepbound / Foundayo for substantially more weight loss.
- Primary goal is HbA1c reduction with weekly dosing. Ozempic (semaglutide 1.0–2.0 mg weekly) and Mounjaro (tirzepatide 5–15 mg weekly) both deliver larger HbA1c reductions than Victoza in head-to-head data.
- Patient preference for oral dosing. Rybelsus (oral semaglutide) and Foundayo (oral orforglipron, approved April 2026) are oral alternatives.
More questions
Should I use Victoza or Ozempic?
Victoza (liraglutide 1.8 mg) and Ozempic (semaglutide 2.0 mg) are both FDA-approved for type 2 diabetes and both have established cardiovascular benefit (LEADER for Victoza, SUSTAIN-6 for Ozempic). Ozempic is dosed once weekly vs Victoza’s once-daily schedule, delivers larger HbA1c and weight reductions on average, and is generally preferred for new T2D patients starting GLP-1 therapy. Victoza retains a role in patients who prefer daily dosing, in patients accessing the Hikma generic for cost reasons, or in patients with documented intolerance or non-response to semaglutide. This is a decision that should be made with a clinician. Our GLP-1 decision quiz walks through the Victoza-vs-Saxenda-vs-Ozempic-vs-Wegovy decision tree.
Further reading
- LEADER trial deep-dive (liraglutide cardiovascular outcomes)
- Top GLP-1 cardiovascular outcomes studies
- Saxenda dose-ladder cheat sheet
- SCALE Maintenance trial deep-dive (liraglutide weight-loss maintenance)
- SCALE Teens trial deep-dive (liraglutide in adolescents 12-17)
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Saxenda · Drugs and brands
- Ozempic · Drugs and brands
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- Mounjaro · Drugs and brands
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- GLP-1 receptor · Mechanism
- Medullary thyroid carcinoma (MTC) · Side effects
Frequently Asked Questions
References
- 1.Marre M, Shaw J, Brändle M, Bebakar WM, Kamaruddin NA, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009. PMID: 19317822.
- 2.Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009. PMID: 18931095.
- 3.Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009. PMID: 18819705.
- 4.Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009. PMID: 19289857.
- 5.Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia. 2009. PMID: 19688338.
- 6.Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009. PMID: 19515413.
- 7.Blonde L, Russell-Jones D. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1-5 studies. Diabetes Obes Metab. 2009. PMID: 19878259.
- 8.Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, et al.; LEADER Steering Committee and Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016. PMID: 27295427.
- 9.Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, et al.; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015. PMID: 26132939.
- 10.Novo Nordisk A/S. VICTOZA (liraglutide) injection, solution — US Prescribing Information. DailyMed (NIH); SetID 5a9ef4ea-c76a-4d34-a604-27c5b505f5a4. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5a9ef4ea-c76a-4d34-a604-27c5b505f5a4
- 11.Novo Nordisk A/S. SAXENDA (liraglutide) injection, solution — US Prescribing Information. DailyMed (NIH); SetID 3946d389-0926-4f77-a708-0acb8153b143. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3946d389-0926-4f77-a708-0acb8153b143
- 12.U.S. Food and Drug Administration. Drugs@FDA structured submission record — VICTOZA (liraglutide), NDA 022341 ORIG-1, original approval January 25, 2010; cardiovascular-mortality-risk-reduction indication added via supplemental approval August 25, 2017. openFDA Drugs@FDA. 2026. https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA022341
- 13.U.S. Food and Drug Administration. Drugs@FDA structured submission record — Liraglutide injection 6 mg/mL (Hikma Pharmaceuticals), ANDA 215503 ORIG-1, submission status AP, approval date December 23, 2024. The first generic GLP-1 receptor agonist approved in the United States; references VICTOZA as the listed drug. openFDA Drugs@FDA. 2026. https://api.fda.gov/drug/drugsfda.json?search=application_number:ANDA215503
- 14.U.S. Food and Drug Administration. Drugs@FDA structured submission record — Liraglutide injection 6 mg/mL (Teva Pharmaceuticals USA), ANDA 214568 ORIG-1, submission status AP, approval date August 27, 2025. Dosed up to 3.0 mg/day for the SAXENDA chronic-weight-management indication. openFDA Drugs@FDA. 2026. https://api.fda.gov/drug/drugsfda.json?search=application_number:ANDA214568
Related research
Saxenda (Liraglutide) for Weight Loss: FDA Label, SCALE Trial Evidence, and the New Teva Generic (2026)
Saxenda (liraglutide 3 mg daily) produced −8.0% weight loss vs −2.6% on placebo in SCALE. Generic liraglutide 3 mg has been FDA-approved since August 27, 2025, and Novo Nordisk is discontinuing the Saxenda brand in early 2027. Wegovy and Zepbound lose more.
13 min read
Trulicity Alternatives: Dulaglutide Decision Guide (Mounjaro, Ozempic, Generics)
Trulicity (dulaglutide) is FDA-approved for type 2 diabetes plus CV risk reduction, not weight management. Alternatives split into four groups: T2D upgrades (Mounjaro, Ozempic), generic liraglutide (Hikma, Teva), weight-management GLP-1s (Wegovy, Zepbound, Foundayo), compounded.
14 min read
Saxenda & Victoza (Liraglutide) and Erectile Dysfunction: The Evidence
Liraglutide (Saxenda, Victoza) offers a real but modest erectile benefit. Obesity and diabetes drive ED through endothelial dysfunction that weight loss can reverse, and liraglutide's weight loss is smaller (~8% in SCALE). There is also a positive signal in hypogonadal men.
9 min read
Saxenda & Victoza (Liraglutide) and Sex Drive: The Honest Evidence
No liraglutide trial measures libido. Saxenda and Victoza are the older, once-daily GLP-1 with smaller weight loss (~8% in SCALE) than Ozempic or Zepbound, so any sex-drive effect is weight-loss-mediated and more modest. Men and women, explained.
9 min read
Saxenda Dosage Chart (2026): The Liraglutide Daily Titration Schedule
The full Saxenda (liraglutide) dose ladder, verified against the FDA DailyMed label: 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg, increasing 0.6 mg weekly, injected once daily. Why it's daily not weekly, missed-dose rules, and Saxenda vs Victoza dosing.
8 min read
Trulicity vs Ozempic vs Mounjaro for T2D: Head-to-Head Evidence
Trulicity (dulaglutide), Ozempic (semaglutide), and Mounjaro (tirzepatide) are the three injectable GLP-1 / GIP-GLP-1 options for T2D. We walk through SUSTAIN-7, SURPASS-2, AWARD-11, and the practical prescribing differences.
11 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Pricing Compare
Get started →Pricing Compare
Get started →Ro
FDA-approved brand GLP-1s, including the Wegovy pill and Foundayo, with insurance help
Read full review →Pricing Compare
Get started →